Baxter International Inc. (BAX) and Halozyme Therapeutics (HALO) announced Monday morning that the FDA has requested additional information to complete its review of the HyQ Biologics License Application.
Baxter International gapped open sharply lower Monday and fell during the first half hour of trade. The stock was range-bound for the remainder of the session and closed down by 3.93 at $54.10 on the highest volume of the year. Baxter sank to over a 2 1/2 month low and fell below its 200-day moving average.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org